Analyst: Price cap on insulin is unlikely to affect drugmakers

The consequences of a new bill capping users’ out-of-pocket insulin expenses in the US will be insignificant for insulin makers including Novo Nordisk, says an analyst.

Photo: Tidsvilde Stine/Ritzau Scanpix

Although US lawmakers took one step closer to securing more affordable insulin for people with diabetes in the US, it’ll be of little consequence for the companies supplying the drugs, including Novo Nordisk, Eli Lilly and Sanofi, assesses Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

On Thursday last week, the US House of Representatives passed a bill that if made law will cap patients’ expenses for a month’s supply of insulin at USD 35.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs